Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clostridia, cluster XIVa, strain relative Clostridium_q symbiosum, live
- Development stage
- Unknown
- Lead developer
- Vedanta Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Clostridia, cluster XIVa, strain relative Clostridium_q symbiosum, live is a defined live commensal bacterial strain used as an active component of Vedanta Biosciences' orally administered microbiome therapeutics. The strain is identified in the VE303 program as VE303-04 and is also listed under the synonyms VE202-16 and JNJ-64841946. It is incorporated into the eight-strain VE303 live biotherapeutic product being evaluated for prevention of recurrent *Clostridioides difficile* infection, and it has also been included in the larger VE202 bacterial consortium evaluated for mild-to-moderate ulcerative colitis. The intended pharmacology is restoration of colonization resistance and beneficial gut microbial metabolism rather than binding to a single human molecular target. ([ctis.eu](https://ctis.eu/trial/2022-502972-22-00))
- Other names
- clostridia, cluster XIVa, strain relative Clostridium_q symbiosum, live
Beyond the preview
Go deeper on clostridia, cluster XIVa, strain relative Clostridium_q symbiosum, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clostridia, cluster XIVa, strain relative Clostridium_q symbiosum, live.